[Cap polyposis and Helicobacter pylori].
Nishiyama
Masahiro
M
Department of Internal Medicine III, Fukuoka University School of Medicine.
Maeda
Kazuhiro
K
Aoyagi
Kunihiko
K
Sakisaka
Syotaro
S
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000368:Aged; D000658:Amoxicillin / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D001944:Breath Tests; D017291:Clarithromycin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D044483:Intestinal Polyposis / Q000453:epidemiology / Q000209:etiology* / Q000473:pathology; D064747:Lansoprazole; D009853:Omeprazole / Q000008:administration & dosage / Q000031:analogs & derivatives; D054328:Proton Pump Inhibitors; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole